SHELTON, CT / ACCESSWIRE / January 13, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing…
PLAINVIEW, N.Y, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leader in human capital, information technology…
CARMEL, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology…
The first selective Fatty Acid Binding Protein 5 inhibitor safely administered to human subjects Initial safety and pharmacokinetic data expected…
Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward…
CAMPBELL, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of…
Reports $709 million in preliminary1 full-year 2024 U.S. net product revenues $611 million in SYFOVRE® U.S. net product revenues, including…
Robust plan benefits powered member growth, mainly driven by switchers from other plansCompany will focus on balancing profitability with strategic…
Fourth Quarter 2024 worldwide revenue of ~$48.8 to $49.0 million representing growth of ~26%Achieved adjusted EBITDA profitability in the fourth…
Entering 2025 having demonstrated rapid translation of genetic insights to positive clinical data; advancing clinically validated and multi-modal pipeline with…